Idenix gets OK for chronic hepatitis B drug,Telbivudine, in Switzerland

[Guest guest]

Idenix gets OK for chronic hepatitis B drug in Switzerland

Idenix Pharmaceuticals Inc. reports the medical regulatory authority for

Switzerland has approved its drug, telbivudine, as a new treatment for

chronic hepatitis B (CHB) in patients with evidence of viral replication and

active liver inflammation.

Telbivudine is a single pill taken orally, once a day, with or without food

to suppress replication of hepatitis B virus.

A new drug application was submitted by Cambridge-based Idenix with the U.S.

Food and Drug Administration in late 2005, and is under review. Regulatory

applications were submitted by its partner Novartis Pharma AG in 2006 in a

number of regions, including the European Union, Canada, Australia,

Switzerland, Taiwan, South Korea, and China, seeking marketing approval of

telbivudine for the treatment of CHB.

Telbivudine is being developed in collaboration between Idenix and Novartis

under a development and commercialization arrangement established in May

2003, along with another hepatitis B clinical product candidate,

valtorcitabine.

http://www.bizjournals.com/masshightech/stories/2006/09/18/daily35.html?from_rss\

=1

_________________________________________________________________

Express yourself - download free Windows Live Messenger themes!

http://clk.atdmt.com/MSN/go/msnnkwme0020000001msn/direct/01/?href=http://imagine\

-msn.com/themes/vibe/default.aspx?locale=en-us & source=hmtagline

[Guest guest]

Idenix gets OK for chronic hepatitis B drug in Switzerland

Idenix Pharmaceuticals Inc. reports the medical regulatory authority for

Switzerland has approved its drug, telbivudine, as a new treatment for

chronic hepatitis B (CHB) in patients with evidence of viral replication and

active liver inflammation.

Telbivudine is a single pill taken orally, once a day, with or without food

to suppress replication of hepatitis B virus.

A new drug application was submitted by Cambridge-based Idenix with the U.S.

Food and Drug Administration in late 2005, and is under review. Regulatory

applications were submitted by its partner Novartis Pharma AG in 2006 in a

number of regions, including the European Union, Canada, Australia,

Switzerland, Taiwan, South Korea, and China, seeking marketing approval of

telbivudine for the treatment of CHB.

Telbivudine is being developed in collaboration between Idenix and Novartis

under a development and commercialization arrangement established in May

2003, along with another hepatitis B clinical product candidate,

valtorcitabine.

http://www.bizjournals.com/masshightech/stories/2006/09/18/daily35.html?from_rss\

=1

_________________________________________________________________

Express yourself - download free Windows Live Messenger themes!

http://clk.atdmt.com/MSN/go/msnnkwme0020000001msn/direct/01/?href=http://imagine\

-msn.com/themes/vibe/default.aspx?locale=en-us & source=hmtagline